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Abstract
GM-CSF is mostly known for its capacity to promote bone marrow progenitor differentiation, to mobilize and mature
myeloid cells as well as to enhance host immune responses. However the molecular actions of GM-CSF are still poorly
characterized. Here we describe a new surprising facet of this ‘‘old’’ growth factor as a key regulator involved in IL-
1bsecretion. We found that IL-1b release, a pivotal component of the triggered innate system, is heavily dependent on the
signaling induced by GM-CSF in such an extent that in its absence IL-1b is only weakly secreted. GM-CSF synergizes with LPS
for IL-1b secretion mainly at the level of pro-IL-1b production via strengthening the NF-kB signaling. In addition, we show
that expression of Rab39a, a GTPase required for caspase-1 dependent IL-1b secretion is greatly augmented by LPS and GM-
CSF co-stimulation suggesting a potential GM-CSF contribution in enhancing IL-1b exocytosis. The role of GM-CSF in
regulating IL-1b secretion is extended also in vivo, since GM-CSF R2/2 mice are more resistant to LPS-mediated septic
shock. These results identify GM-CSF as a key regulator of IL-1b production and indicate GM-CSF as a previously
underestimated target for therapeutic intervention.
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Introduction
Dendritic cells (DCs) and macrophages (MØ), the major
sentinels of the innate immune system, are probing and
recognising microbes and danger signals via specific pattern-
recognition receptors. The resultant intracellular signalling
cascades lead to the maturation and to secretion of several pro-
inflammatory cytokines, such as IL–1 (IL-1a and b), TNF-a, IL-6.
All these cytokines are ultimately involved in the pathogen
elimination by promoting and sustaining an effective adaptive
immune response [1].
IL-1b is a particularly potent pyrogenic cytokine and a key
modulator involved in the regulation of immune responses against
a variety of microbes as well as in several acute and chronic
inflammatory disorders and septic shock [2]. Differently to other
pro-inflammatory cytokines, the secretion of the active form of IL-
1 is a tightly controlled two-step process which includes (i) the
synthesis of the pro- IL-1b and (ii) its processing into a mature
active IL-1b followed by its secretion. The generation of the active
IL-1b via cleavage of its cytoplasmic proform is strictly dependent
on caspase-1, a component of multi protein complexes, the best
characterized being the NLRP3 inflammasome [3][4].
The tightly controlled production and secretion of IL-1b typically
requires two separate ‘‘external’’ signals. The first signal, provided
by several pathogen-associated molecular patterns (PAMPs),
promotes transcription, production and intracellular accumulation
of the cytokine pro-form. The second signal, sometimes called
‘‘danger’’ signal is mediated by ATP, uric acid and aluminium salt
(Alum) and many other factors, is needed for NLRP3 and caspase-1
activation and subsequent release of the biological active form of the
cytokine. To avoid uncontrolled NLRP3 priming, its activation is
strictly dependent on the PAMP-mediated NF-kB activation which
regulates also the expression of NLRP3 [5,6].
This multi-level control ensures that the highly pyrogenic and
inflammatory IL-1b is secreted only under circumstances when an
inflammatory response is required. The loss of this stringent
control can lead to autoinflammatory disorders, such as familial
Mediterranean fever, familial cold autoinflammatory syndrome
and Muckle-Wells syndrome. All these inflammatory diseases
respond to specific IL-1b or caspase-1 rather than TNF-a blocking
therapies [7]. Hence a better understanding of the pathways
controlling inflammasome activation and IL-1b release will
potentially lead to the identification of new targets for therapeutic
intervention.
Although GM-CSF was originally characterized as a haemato-
poietic growth factor responsible for the differentiation of bone
marrow (BM) progenitor cells [8], in the last years it has been
recognized as a key pro-inflammatory cytokine during inflamma-
tion or in response to infection [9]. A variety of studies have shown
its contribution to promoting survival and activation of MØ,
neutrophils, eosinophils and DCs, in mobilizing myeloid popula-
tions into the blood [10] as well as in enhancing host defense
mechanisms against various bacterial and fungal infections [11]. In
this study, we have identified a new function for GM-CSF as a
crucial factor in the regulation of the multi-step process required
for an efficient IL-1 release. Antigen presenting cells exploit GM-
CSF as a licensing factor, which controls the transcriptional
induction of IL-1b. This surprising new insights into ‘‘an old
factor’’ high-lights the recently emerging picture of GM-CSF as a
front-line cytokine driving inflammation.
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GM-CSF boosts dramatically LPS-induced IL-1 secretion
To test the effects of GM-CSF on the cytokine production in
‘‘danger situation’’ we stimulated FLTL3- derived DC in the
presence of ATP with LPS alone or in combination with GM-
CSF. Cultures were then measured for their contents of several
pro-inflammatory cytokines, such as of IL-1a, IL-1b, TNF-a, and
IL-6. GM-CSF alone did not induce any cytokine release but to
our surprise combination with LPS dramatically enhanced the
secretion of IL-1s with all tested concentrations of LPS about ten
fold (Fig. 1A). Interestingly, no effect was seen for TNF-a release,
while IL-6 production was only slightly increased (2-fold) (Fig. 1A).
GM-CSF did not act as a danger signal itself since it always needs
to partner with ATP or any other tested known danger signals,
such as nigericin, MSU or Alum (Fig. 1B), whereas, as expected ,
TNF-a and IL-6 were released (Fig. 2, middle and right panel).
Furthermore, we observed that the synergistic effect of GM-CSF
was not restricted to classical TLR-agonists, such as LPS,
Pam3CysSK4, since GM-CSF strongly amplified also the IL-1b
secretion in response to other non TLR-specific microbial stimuli
such as the Dectin-1 ligand Curdlan as well as TNF-a cytokine
(Fig. 1C).
We then extended our analysis to other APCs, such as GM-CSF
derived BM DCs, M-CSF-derived BM MØ as well as L929
conditioned supernatant -derived BM MØ, focusing on the IL-1b
secretion profile. In this study, we did not analyse the secretion
profile of neutrophils, known to be one of the major IL-1b
producers, since they secrete Il-1b independently from caspase-1
[12] which is indispensable for MØ and DCs. In all cases striking
synergism as above was observed (Fig. 1D). As expected the same
target cell populations derived from GM-CSFR2/2 BM cells
Figure 1. GM-CSF boosts LPS-induced IL-1 secretion. (A) CD11b
+ fraction of FLT3L derived DCs was stimulated 24 h with a wide range of
different LPS concentrations (0.001–10 mg/ml) in absence (white circles) or presence of 5 ng/ml GM-CSF (black circles). 5 mM ATP was added as a
danger signal. Released IL-1b, IL-1a, TNF-a and IL-6 were measured in the culture supernatants by standard ELISA and each value represents the
mean of triplicates +/2 SD. (B) CD11b
+ fraction of FLT3L generated DCs was primed for 24 h with 100 ng/ml LPS with (back bars) or without (white
bars) 5 ng/ml GM-CSF and stimulated with different danger signals (5 mM ATP, 1 mM nigericin, 100 mg/ml MSU, 200 mg/ml Alu). Each bar represents
the mean of triplicates +/2 SD. (C) CD11b
+ fraction of FLT3L generated DCs was primed with TLR agonists (100 ng/ml LPS and Pam3CSK4), Dectin
agonist, Curdlan (100 mg/ml) and pro-inflammatory cytokine TNF-a (100 ng/ml) in absence (white bars) or presence (back bars) of 5 ng/ml GM-CSF
and stimulated subsequently with ATP. Each bar represents the mean of triplicates +/2 SD. (D) GM-CSF derived BM DCs, M-CSF-derived BM MØ as
well as L929-derived BM MØ were compared to the CD11b
+ fraction of FLT3L-derived DCs for their capacity to secrete IL-1b upon 24 h LPS
stimulation (100 ng/ml) in absence or in presence of GM-CSF (5 ng/ml). ATP was added as danger signal. Both, WT (black bars) and GM-CSF R2/2
cells (white bars) were tested. Each bar represents the mean of triplicates +/2 SD. All results are representative of at least two independent
experiments.
doi:10.1371/journal.pone.0023025.g001
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responses were generated by GM-CSF derived DCs which were
probably optimally primed already during their generation. Of
note, robust (ng/ml level) IL-1 responses observed in earlier
reports can probably be attributed to residual presence of GM-
CSF. In absence of this growth factor, IL-1 levels tend to reach
much lower levels in the pg/ml range.
To exclude the acquisition of tolerance due to prolonged
stimulation with LPS [13], we tested shorter incubation periods
ranging from 3 h to 9 h. Similarly to the results obtained after
24 h LPS treatment, higher levels of IL-1b were detectable only
when FLT3L-derived CD11b
+ DCs were co-incubated with GM-
CSF (Fig. 2, left panel). In the case of the other measured
cytokines, TNF-a and IL-6, the effect of GM-CSF on their release
was moderate and comparable the result described in Fig. 1A
(Fig. 2, middle and right panel).
Interestingly GM-CSF proved to be the most potent modulator
of IL-1b secretion, since other known inflammatory cytokines did
not mediate the same effect in DCs. In fact, none of the tested
cytokines including M-CSF, IL-6, IFN-c and TNF-a stimulated
efficiently DCs to release high amounts of IL-1b when co-applied
with LPS (Fig. S1).
Taken together, these results indicate that require GM-CSF for
a robust IL-1b secretion in response to several microbial and non-
microbial stimuli.
GM-CSF synergises LPS-induced pro-IL-1b synthesis via
increased activation of NF-kB but does not affect
caspase-1 cleavage
An efficient IL-1b secretion requires aNFkB-dependent synthe-
sis of pro-IL-1b followed by a required danger signal which
mediates the activation of the caspase-1.
To clarify whether GM-CSF acts at the level of IL-1b synthesis,
of its processing or plays a role in both pathways, DCs and MØ
were stimulated overnight with LPS in the absence or in the
presence of GM-CSF. Western blot analysis showed five-times
higher amounts of the pro IL-1b form in cells stimulated with the
combination of LPS and GM-CSF as compared to cells treated
with LPS alone (Fig. 3A). Together with IL-1b we measured also
the content of the inflammasome components, such as NLRP3,
caspase-1 and -11 in untreated and differently stimulated cells. As
shown in Fig. 3A, caspase-1 protein levels were similar in all tested
conditions in both DCs and MØ, whereas NLRP3 and caspase-11
levels were increased upon stimulation, but without any obvious
difference between LPS and LPS/GM-CSF treatments.
In this context, we tested the effect of two different NF-kB
inhibitors (Bay11-7082 and Wedelolactone) on DCs treated with
LPS alone or the LPS/GM-CSF combination. The secretion of
IL-1b was clearly dose-dependently decreased by both inhibitors
pointing to a crucial role of GM-CSF in sustaining NF-kB
activation (Fig. 3B). The decrease was not caused by a possible
cytotoxicity effect of the inhibitors, since a 1–3 mM Bay 11-0782
and 30 mMWedelolactone concentration caused around 80% IL-
1b inhibition without any detectable effect on cell viability (Fig.
S2). In addition, augmented NF-kB activation via the combination
of LPS and GM-CSF could be clearly visualized by measuring a
strong augmented nuclear translocation of NF-kB subunits p65,
p50, p52 as well as c-Rel only upon stimulation with both stimuli
as illustrated in Fig. 3C.
We then analysed the proteolytic processing of pro-caspase-1
triggered by nigericin in WT and in GM-CSF R2/2 MØ upon
LPS stimulation in presence or absence of GM-CSF. The cleavage
of the active form of the enzyme, p20 was clearly detectable in
both WT and GM-CSF R2/2 cells independently whether GM-
CSF was co-applied (Fig. 4). However, the mature IL-1b (p17) was
efficiently released in the culture supernatant by MØ stimulated
with the LPS/GM-CSF combination, result which could be
confirmed either by western blot or by ELISA measurement.
These results demonstrate that GM-CSF is crucial for efficient
priming of the pro-IL-1b form synthesis via strengthening the NF-
kB signalling but it is dispensable for the caspase-1 activation.
GM-CSFR2/2 mice are more resistant to LPS-induced
septic shock
It is commonly accepted, that excessive production of pro-
inflammatorycytokinessuchasTNF-a and inparticularIL-1,isone
of the major causes of septic shock induced by endotoxin. To
determine whether GM-CSF contributes to septic shock, we
injected 50 mg/g LPS i.p. and both mouse survival and serum
cytokine levels were monitored in WT and GM-CSF R2/2 mice.
At this high concentration, LPS induces a caspase-1 dependent
endotoxin shock caused by elevated levels of pro-inflammatory
cytokines like TNF-a and IL-1b [14][15]. In line with the observed
effectsofGM-CSFinboosting IL-1 secretion,itis not a surprise that
GM-CSF R2/2 mice are more resistant to LPS-mediated septic
shock. In fact, as shown in Fig.5A, 80% of the WT micedied within
the first two days, whereas 10 out of 12 GM-CSFR2/2 mice were
resistant to the lethal LPS injection and survived up to 7 days. In
addition, GM-CSFR2/2 mice had lower levels of serum IL-1b
(*** P,0.001), TNF-a (** P,0.01) and IL-1a (* P,0.1) after LPS
injection (Fig. 5B).
Rab39a expression is greatly enhanced by LPS and
GM-CSF co-stimulation
It was recently shown that over expression of Rab39a, a
member of the RabGTPase family, leads to an enhancement of
Figure 2. CD11b
+ fraction of FLT3L derived DCs were stimulated for 3, 6, 9 and 24 h respectively with LPS alone (white bars) or in
combination with GM-CSF (black bars). For the detection of IL-1b,4 610
5 cells were stimulated for 1 h with ATP, for IL-6 and TNF-a the cytokine
release of 1610
5 cells was analysed without ATP treatment. Released cytokines were measured by ELISA. Each bar represents the mean of triplicates
+/2 SD.
doi:10.1371/journal.pone.0023025.g002
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agonists, like MALP2, LPS and Pam3Cys [16]. To investigate the
effect of GM-CSF on its expression levels, we analysed by qPCR
the Rab39a and, as a control, the related Rab39b mRNA levels
upon DCs and MØ stimulation with LPS and LPS/GM-CSF,
respectively. As shown in Fig. 6, in both cell types the combination
of LPS and GM-CSF lead to enhanced Rab39a upregulation
when compared to LPS and GM-CSF alone. The profile of the
Rab39b mRNA, another member of the RabGTPase family but
without caspase-1 binding property, remained unchanged.
Discussion
Although GM-CSF was originally characterized as a haematopoi-
etic growth factor responsible for the differentiation of BM progenitor
cells and mobilization of myeloid cells, in the last years GM-CSF
has been recognized as a key pro-inflammatory cytokine during
inflammation or in response to infection [9][10,11]. This property is
exploited in many vaccination strategies where GM-CSF is included to
boost the immune responses [17][18][19][20][21]. Similarly to CD40-
mediated DC maturation [22], GM-CSF supports the formation
of potent ‘‘effector’’ DCs capable in secreting a variety of pro-
inflammatory cytokines only when combined with microbial stimuli
[23]. In fact, combinations of GM-CSF with different TLR agonists,
like LPS, CpG, PolyI:C and Zymosan augmented clearly IL-12p70
secretion [23] as well as IL-6 and some TNF-a release as described
here in this paper. Indeed, GM-CSF was previously shown to regulate
cytokine production by MØ due to upregulation of CD14 and TLR4
[24][25].
Here we describe a novel and unexpected finding that GM-CSF
can act as a strong synergistic enhancer of the inflammasome-
dependent IL-1b secretion in response to NF-kB activating
agonists, such as LPS, TNF-a and Dectin-1 ligands. In fact,
unlike TNF-a, IL-6 and IL-12 whose secretion can be maximally
increased only about 2-fold by the LPS/GM-CSF co-stimulation,
microbial-induced IL-1b secretion can be synergistically augment-
ed by GM-CSF up to 10-fold. Our data strongly suggest that GM-
CSF acts as enhancer of the synthesis of the pro IL-1b form. The
enhanced pro-IL-1b levels could be explained by the GM-CSF
ability to regulate the IL-1b gene expression at transcriptional as
well as post-translational levels as shown by Fernandez et al in
human polymorphonuclear leukocytes [26].
In addition, we could rule out its role in the cleavage process
required for the formation of the IL-1b active form which is
actually stimualted by many so called ‘‘danger signals’’ such as
extracellular ATP, Alum as well as uric acid. Interestingly, GM-
CSF revealed to be the most potent modulator of the IL-1b
secretion when compared to other pro-inflammatory cytokines,
such as TNF-a, IL-6, INF-c and M-CSF, which hardly primed its
release. Furthermore, the observed synergistic enhancement of
pro-IL-1b synthesis upon co-stimulation with LPS/GM-CSF is not
a consequence of an augmented GM-CSF-mediated cell survival
since no difference in number of viable cells between the two
stimulated groups (LPS versus LPS/GM-CSF) was observed
Figure 3. GM-CSF amplifies LPS-induced pro-IL-1b synthesis via enforcement of NF-kB activation. (A) Western blot analysis of pro-IL-1b,
NLRP3, caspase-1 and -11 in FLT3L derived CD11b
+ DCs and L929-derived BM MØ. Cells were left untreated or stimulated overnight with 100 ng/ml
LPS, 5 ng/ml GM-CSF or a combination of both and cell lysates were subsequently prepared and separated on a 10% SDS-PAGE gel. (B) Dose-
dependent inhibition of IL-1b secretion via two different NF-kB inhibitors, Bay 11-7082 and Wedelolactone. FLT3L derived DCs were pre-treated for
30 min with different concentration range of inhibitors, stimulated and analysed as described in Fig. 1. White circles: LPS; Black circles: LPS and GM-
CSF. Each bar represents the mean of triplicates +/2 SD (C) Nuclear recruitment of NF-kB subunits in FLT3L-derived CD11b
+ DCs was analyzed by
DNA-binding ELISA (p50, p52 and p65) and western blot (c-Rel). Results illustrated were confirmed in two independent experiments.
doi:10.1371/journal.pone.0023025.g003
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(unpublished data).
Although we have related the ‘‘GM-CSF phenomenon’’ to
increased synthesis of pro-IL-1b it is possible, maybe likely, that
GM-CSF signalling could also influence molecular pathways
controlling the still mysterious and unconventional secretion of IL-
1b. In fact, it is reported that GM-CSF triggers granule exocytosis
in human neutrophils [27]. In this context, we show that GM-CSF
greatly augmented the expression of the trafficking adaptor
Rab39a, a recently discovered GTPase which links caspase-1 to
IL-1b secretion. [16]. This suggests that GM-CSF can have a role
also in extracellular IL-1b release.
GM-CSF/LPS combination also increased greatly the expres-
sion of NLRP3, caspase-1 and caspase-11 mRNAs in several
experiments (although not detected in our conditions at protein
level, unpublished observations) suggesting that in some unknown
situations the protein levels of the most inflammasome compo-
nents can be further boosted.
How GM-CSF amplifies this massive pro-IL-1b synthesis is still
elusive. Based on our results, it is clear that the GM-CSF and LPS
induced intracellular pathways have to cross-talk upon co-
engagement of the correspondent receptors. It is well documented
that GM-CSF activates the Jak2/STAT5, Ras/Raf/MAPK as
well as PI3K/Akt pathways through its heterodimeric receptor
composed by a major binding unit GMRa and a major signalling
unit GMRbc (reviewed in [10,28,29]). Interestingly, there is also
evidence suggesting the involvement of GM-CSF in the activation
of the NF-kB signalling pathway. Ebner et al. elegantly showed
using a two-hybrid yeast system that IkB kinase (IKK) b associates
with the GM-Ra subunit [30], whereas Nakamura et al.
demonstrated that signals downstream the bc induce a STAT5-
dependent increase of NF-kB binding and trans activation in
murine proB cells [31]. More recently, Meads et al. proposed a
new model which suggests TNF receptor-associated factor 6
binding domain (TRAF6) as an intracellular adaptor for GM-
CSF-induced NF-kB activation demonstrating for the first time
that TRAFs are important signalling intermediates not only for
TNFRs and TLRs but also for class I cytokine receptors, such as
GM-CSF R [32]. In addition, it has been recently shown that Ik-
Bb operates as an important co-activator for LPS-induced IL-1b
transcription through its recruitment to their specific promoter in
complex with two other NF-kB subunits p65/RelA and c-Rel
[33,34]. Our results show that the nuclear translocation of both
p65/RelA as well c-Rel was detectable in the case of LPS
stimulation but was clearly strongly enforced when DCs were
stimulated with the combination of both stimuli.
It is commonly accepted, that excessive production of pro-
inflammatory cytokines such as TNF-a and IL-1 is one of the major
causes of septic shock induced by bacterial endotoxin. In line with
the observed effects of GM-CSF in boosting IL-1 secretion, it is not
a surprise that GM-CSF R2/2 mice are more resistant to LPS-
mediated septic shock. Interestingly, IL-1b deficient mice are
sensitive to LPS induced shock while GM-CSF R2/2 mice show
resistance comparable to caspase-1 [15,35], caspase-11 [36], ASC
[37], Ik-Bb [33,34] and CIAS1 (cryopyrin) [38] deficient mice. The
LPS resistance observed in our study is in accordance with data
published some years ago by Basu et al. who reported an enhanced
tolerance to LPS in GM-CSF deficient mice [39]. Similarly to our
results, after LPS treatment reduced circulating levels of IL-1a and
IL-6 were detected whereas TNF-alevels in the serum were
comparable to those in control mice. Furthermore, treatment with
anti-GM-CSF neutralizing antibody protects mice against a lethal
endotoxin dose underlying the role of GM-CSF as endogenous
enhancer of LPS-mediated toxicity [40]. In fact, GM-CSF serum
content is elevated after LPS injection although in much lower
extent than the level of prototype endotoxin-induced TNF-a.
However even tiny amounts of GM-CSF (as low as 100 pg/ml) are
effective in priming the maturation of DCs and boosting the LPS
induced IL-1 production (data not shown).
In conclusion, we have shown here that GM-CSF is a sensitive
and strong amplifier of IL-1 release after bacterial infections or
after many inflammatory triggers. Since many inflammatory
diseases respond to specific IL-1b or caspase-1 blocking therapies
[7], our data suggest to include GM-CSF as an additional
potential target in the development of more efficient therapeutic
strategies against inflammasome-related autoinflammatory diseas-
es. Furthermore, a better understanding of the molecular basis of
this synergistic activity mediated by GM-CSF will provide new
exciting insights on how to tailor more efficient vaccination
strategies.
Materials and Methods
Mice
B6.129S1-Csf2rb
tm1Cgb/J (GM-CSF receptor2/2) and C57BL/
6 mice were obtained from The Jackson Laboratories (Maine,
USA), bred and maintained in the animal facility of the Nanyang
Technological University under specific pathogen-free conditions.
Reagents
TLRgrade
TM LPS was purchased from Alexis (Enzo Life
Sciences, Alexis, Lausen, Switzerland), Bay 11-7082, Wedelolac-
tone, Alum, Pam3CysSK4 and Curdlan from Sigma (St Louis,
MO, USA), MSU, ATP, Nigericin from InvivoGen (San Diego,
CA, USA). Following antibodies were used for western blotting:
Figure 4. LPS and LPS/GM-CSF induce equal cleavage of
caspase-1 in presence of a danger signal. Measurement of
bioactive secreted IL-1b p17 and active caspase p20 in serum free
culture supernatants of WT and GM-CSFR2/2 L929-derived BM MØ
treated overnight with 100 ng/ml LPS, 5 ng/ml GM-CSF or a
combination of both and then pulsed for 1 h with Nigericin. Upper
panel shows the quantification of the amount of IL-1b released
measured by ELISA. Results are representative of two independent
experiments.
doi:10.1371/journal.pone.0023025.g004
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Cruz Biotechnlogy, Santa Cruz, CA, USA), anti-IL-1b antibody
(R&D), anti-NLRP3 (Alexis), anti-caspase-11 (Biolegend, San
Diego, CA, USA). Recombinant GM-CSF, TNF-a, IL-6 and
IFN-c were obtained from Biolegend, M-CSF from Milteny
Biotech (BergischGladbach, Germany).
BM-derived DCs and MØ
GM-CSF and FLT3L-derived BM DCs were generated by
incubating freshly prepared BM cells for 8 days in IMDM medium
supplemented with 20 ng/ml GM-CSF or 100 ng/ml FLT3L,
respectively. In the case of the FLT3L generated DCs, CD11b
+
cells were purified by magnetic separation (MiltenyiBiotec). Two
types of MØ were generated from BM cells using L929
cellconditioned medium (30%) (L929-derived BM Mw)o r
20 ng/ml M-CSF (M-CSF-derived BM Mw), respectively.
Cytokine measurements
Cells were stimulated overnight with LPS with or without GM-
CSF and subsequently treated for 1 h or 6 h with different danger
signals (5 mM ATP, 1 mM nigericin, 100 mg/ml MSU and
200 mg/ml Alum) and cell supernatant was analysed for IL-6,
TNF-a, IL-1a and -b by ELISA following manufactures
instructions (Biolegend).
Quantitative RT-PCR
CD11b
+ fraction of FLT3L generated BM DCs and L929-
derived BM MØ were stimulated for 24 hours with 100 ng/ml
Figure 5. GM-CSF R2/2 mice survive LPS-induced septic shock. (A) Survival of WT and GM-CSFR2/2 mice ( n=12 each group) injected i.p.
with 50 mg/g body weight LPS. (B) WT and GM-CSFR2/2 mice were bled from the retro-orbital plexus 3 h after LPS treatment. Pro-inflammatory
cytokines such as IL-1a, IL-1b, IL-6 and TNF-a were measured in the serum by ELISA. The data represent the mean +/2 SD of three pooled
independent experiments. *,0.1, ** P,0.01, *** P,0.001 (Student’s t test).
doi:10.1371/journal.pone.0023025.g005
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extracted using the Pure Link RNA Isolation Kit (Invitrogen) as
per manufacturer’s instructions and cDNA was prepared. SYBR
green I-based quantitative real-time PCR (QPCR) was performed
following manufacture’s protocol (KabaSyBR FAST qPCR Kit,
Kababiosystem, Woburn, MA). Rab39a and Rab39b expression
was calculated using a comparative method for relative quantita-
tion upon normalization to HPRT gene expression.
Western blotting
For detection of the pro IL-1b, caspase-1, caspase-11, NLRP3
and tubulin, as an internal control, lysates of L929-derived MØ
and FLT3L-derived DCs were resolved by SDS-PAGE and equal
amounts transferred onto nitrocellulose membranes. The blots
were developed by chemiluminescence according the manufac-
tures instructions (Perkin Elmer, Waltham, MA, USA).
For detection of the caspase-1 cleaved p20 subunit as well as of
the bioactive IL-1b p17 form, L929-derived BM MØ were
incubated overnight untreated or with 5 ng/ml GM-CSF,
100 ng/ml LPS or the combination of 5 ng/ml GM-CSF and
100 ng/ml LPS, respectively. After 1 h stimulation with 1 mM
nigericin, supernatants were collected and equal amounts of
concentrated fractions were separated by SDS-PAGE.
To measure nuclear NF-kB subunits p65, p50, p52 and c-Rel
levels, FLT3L-derived CD11b
+ DCs were kept untreated or
stimulated for 20 h with 5 ng/ml GM-CSF, 100 ng/ml LPS or
the combination of 5 ng/ml GM-CSF and 100 ng/ml LPS,
respectively. NF-kB DNA binding activity of p65, p50, p52 was
determined using a DNA-binding ELISA kit (TransAM NF-kB
transcription factor kit, Active Motif, Carlsbad, CA, USA) using
equal amounts of nuclear extracts. c-Rel and USF-2 as an internal
standard were monitored by western blotting.
LPS-induced septic shock
WT and GM-CSFR2/2 mice (6–8 weeks old) were i.p. injected
with 50 mg/g of LPS from E.coli (055:B5, Sigma) The mice were
monitored for sign of septic shock and for lethality over a period of 7
days.Forserumcytokineanalysis,micewerebled3 haftertreatment.
Data analysis
Calculations, statistical analysis and graphs were performed on
Graphpad Prism 4.0 (Graphpad Software, San Diego, USA).
Ethics statement
This study was carried out in strict accordance with the
recommendations of the NACLAR (National Advisory Committee
for Laboratory Animal Research) guidelines under the Animal & Birds
(Care and Use of Animals for Scientific Purposes) Rules of Singapore.
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Supporting Information
Figure S1 CD11b
+ FLT3L generated DCs (3610
5/well)
were primed for 24 h with 100 ng/ml LPS in absence
(white bars) or presence (back bars) of 5 ng/ml GM-
CSF, 50 ng/ml M-CSF, 50 ng/ml TNF-a, 50 ng/ml IL-6,
50 ng/ml IFN-c. 5 mM ATP was added for the last 1 h as a
danger signal. Released IL-1b was measured in the culture
supernatants by standard ELISA and each value represents the
mean of triplicates +/2 SD.
(TIFF)
Figure S2 Effect of Bay 11-7082 and Wedelolactone on
DC viability. FLT3L derived DCs were pre-treated for 30 min
with a different concentration range of inhibitors, stimulated as
described in Fig. 1. White bars: LPS; Black bars: LPS and GM-
CSF Cells were stained with propidium iodide and analyzed by
FACS gating of FCS/SSC. % of viable cells is indicated.
(TIF)
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